Literature DB >> 8957581

Immunomodulatory action of levofloxacin on cytokine production by human peripheral blood mononuclear cells.

T Yoshimura1, C Kurita, E Usami, T Nakao, S Watanabe, J Kobayashi, F Yamazaki, H Nagai.   

Abstract

Levofloxacin (LVFX), the bacteriologically active isomer of ofloxacin, is a fluorinated quinolone. LVFX suppressed the proliferative activity of peripheral blood mononuclear cells (PBMC) stimulated with phytohemagglutinin (PHA). LVFX increased interleukin-2 (IL-2) production by PBMC stimulated with PHA in a dose-dependent manner, with more than 10 micrograms/ml of LVFX causing a significant increase. The granulocyte-macrophage colony-stimulating factor and soluble IL-2 receptor production by PHA-stimulated PBMC was suppressed at high concentrations of LVFX. Interleukin-1 beta production by lipopolysaccharide-stimulated PBMC was suppressed in a concentration-dependent manner by LVFX, and tumor necrosis factor-alpha production was suppressed at only the highest concentration. In contrast, interleukin-8 production was little affected by LVFX. These results show that LVFX has an immunomodulatory action on cytokines production by PBMC independent of its antimicrobial activity.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957581     DOI: 10.1159/000239480

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  9 in total

1.  The 6-fluoro-8-methoxy quinolone gatifloxacin down-regulates interleukin-8 production in prostate cell line PC-3.

Authors:  Koh Takeyama; Hiroaki Mitsuzawa; Chiaki Nishitani; Takeyuki Shimizu; Hitomi Sano; Yasuharu Kunishima; Satoshi Takahashi; Hiroshi Hotta; Masanori Matsukawa; Ken-Ichiro Shibata; Taiji Tsukamoto; Yoshio Kuroki
Journal:  Antimicrob Agents Chemother       Date:  2006-10-16       Impact factor: 5.191

Review 2.  Chronic prostatitis/chronic pelvic pain syndrome: a review of evaluation and therapy.

Authors:  A S Polackwich; D A Shoskes
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-03-08       Impact factor: 5.554

3.  Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a beta-lactam versus a fluoroquinolone.

Authors:  Esther Calbo; Montserrat Alsina; Mónica Rodríguez-Carballeira; Josep Lite; Javier Garau
Journal:  Antimicrob Agents Chemother       Date:  2008-04-21       Impact factor: 5.191

4.  Anti-inflammatory effects of moxifloxacin on activated human monocytic cells: inhibition of NF-kappaB and mitogen-activated protein kinase activation and of synthesis of proinflammatory cytokines.

Authors:  Taly Weiss; Itamar Shalit; Hannah Blau; Sara Werber; Drora Halperin; Avital Levitov; Ina Fabian
Journal:  Antimicrob Agents Chemother       Date:  2004-06       Impact factor: 5.191

5.  Levofloxacin inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells.

Authors:  Mutsuo Yamaya; Hidekazu Nishimura; Yukimasa Hatachi; Hiroyasu Yasuda; Xue Deng; Takahiko Sasaki; Katsumi Mizuta; Hiroshi Kubo; Ryoichi Nagatomi
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

Review 6.  Role of bacteria in chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Vi N Hua; Daniel H Williams; Anthony J Schaeffer
Journal:  Curr Urol Rep       Date:  2005-07       Impact factor: 2.862

7.  Sustainable waste management and recycling of Zn-Al layered double hydroxide after adsorption of levofloxacin as a safe anti-inflammatory nanomaterial.

Authors:  Samar M Mahgoub; Mohamed R Shehata; Fatma L Abo El-Ela; Ahmed Farghali; Amal Zaher; Rehab K Mahmoud
Journal:  RSC Adv       Date:  2020-07-23       Impact factor: 4.036

8.  Effects of awakening and the use of topical dexamethasone and levofloxacin on the cytokine levels in tears following corneal transplantation.

Authors:  Mariann Fodor; Goran Petrovski; Dorottya Pásztor; Péter Gogolák; Éva Rajnavölgyi; András Berta
Journal:  J Immunol Res       Date:  2014-10-12       Impact factor: 4.818

9.  Levofloxacin might be safe to use for OSCC patients.

Authors:  Levent Aydemir; Elif Sinem Iplik; Baris Ertugrul; Goksu Kasarci; Merve Nur Atas; Murat Ulusan; Arzu Ergen; Bedia Cakmakoglu
Journal:  Med Oncol       Date:  2021-06-25       Impact factor: 3.064

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.